Cancer patients with relatively stable chronic background pain may experience transient
episodes of pain, known as breakthrough cancer pain (BTP). There is no universally …

Breakthrough pain (BTP) in patients with cancer lacks a consensus definition and is
subsequently inadequately diagnosed and assessed, therefore making it more challenging …

The treatment of breakthrough pain (BTP) in cancer patients is often sub-optimal. Normal-
release oral opioid formulations have a slow onset of action, such that the episode of pain …

Background: The aim of this study was to identify potential variables influencing the clinical
presentation of breakthrough cancer pain (BTP). Methods: Cancer patients with a diagnosis …

Background Confusion remains over the definition of breakthrough cancer pain (BT cP)
potentially leading to delayed diagnosis and treatment. Methods An on‐line survey was …

Breakthrough pain (BTP) has been defined as a transient exacerbation of pain that occurs to
patients with otherwise stable baseline persistent pain. It is one of the most prevalent and …

Objectives Breakthrough cancer pain (BTP) represents a treatment challenge. Objectives
were to examine the prevalence and characteristics of BTP in an international sample of …

Breakthrough cancer pain (BTCP) is defined as a transient exacerbation of pain that arises
in patients with otherwise controlled persistent pain. BTCP typically has a rapid onset and …

Objective: The efficacy of intranasal fentanyl spray (INFS) was compared with that of oral
transmucosal fentanyl citrate (OTFC) for the relief of cancer-related breakthrough pain (BTP) …

Breakthrough pain (BTP), a transitory exacerbation of pain superimposed on a background
of persistent, usually adequately controlled pain, has been reported to occur in 50% to 75 …